Clinical-stage regenerative biologics and exosome therapeutics
Strategic Profile
As of July 2025, ZEO is spearheading an expansion initiative aligned with Florida's new SB-1768 stem cell law, with Florida now authorizing the use of non-FDA-approved stem cell therapies compliant with the new regulations. In April 2026, the company was selected as a Qualified Team advancing into the Semi-Finals stage of the XPRIZE Healthspan, a $101 million global competition designed to revolutionize human aging.
Cyborg Score Rationale
Early-stage clinical biotech with differentiated exosome platform and recent XPRIZE selection validates technology, but micro-cap scale ($14.8M market cap, $5.55M TTM revenue) and OTC listing create execution risk. Strong momentum from Florida regulatory tailwind and successful clinical phase progression provide growth catalysts.
Top Insights
Selected as Qualified Team in XPRIZE Healthspan Semi-Finals (April 2026), competing in $101M competition focused on restoring muscle, cognitive, and immune function in 65-80 year-olds.
Lead product Zofin (acellular biologic) in Phase I/II clinical trials for COVID-19, COPD, osteoarthritis, and traumatic brain injury.
Positioned for Florida market expansion post-SB-1768 stem cell law with FDA-registered, cGMP-compliant manufacturing and physician education platform.
Company rebranded from Organicell Regenerative Medicine to Zeo ScientifiX in February 2024, ticker changed to ZEOX.
Named Competitors
Cell therapy platforms — Cell therapy and regenerative medicine developer
Cell therapy and exosome therapeutics — Allogenic cell therapy platform
Psychedelic and regenerative therapeutics — Mental health and regenerative medicine developer
Recent Developments
(April 2026) Selected as Qualified Team advancing to XPRIZE Healthspan Semi-Finals for aging-biology therapeutics competition
(July 2025) Launched expansion initiative to capitalize on Florida's new SB-1768 stem cell law with turnkey product platform and physician partnerships
(February 2024) Rebranded from Organicell Regenerative Medicine, Inc. to Zeo ScientifiX, Inc.; began trading under ticker ZEOX
Open the full interactive Zeo ScientifiX, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.